[ICD 10 Search]

Back
[ICD 10 Search]

Congestive heart failure

**{{{Name|Congestive heart failure}}}**
[[Image:{{{Image}}}\|190px\|center\|]] {{{Caption\|}}}
ICD-10	I50.0
ICD-O:	{{{ICDO}}}
ICD-9	428.0
OMIM	}}}
MedlinePlus	}}}
eMedicine	}}}
DiseasesDB	}}}

Congestive heart failure (CHF) (also called congestive cardiac failure and heart failure) is the inability of the heartto pump a sufficient amount of bloodthroughout the body, or requiring elevated filling pressures in order to pump effectively.

CHF is an abnormal cardiac condition that reflects impaired cardiac pumping and blood flow. The pooling of blood leads to congestion in body tissue.

The term heart failure is frequently misused, especially when given as cause of death: it is not synonymous with "cessation of heartbeat" – for which see cardiac arrest. Because not all patients have volume overload at the time of initial or subsequent evaluation, the term "heart failure" is preferred over the older term "congestive heart failure". However, a fatal heart attack can happen as a result of CHF, when the heart is too exhausted to beat.

Inhaltsverzeichnis

1 Causes
2 Classification
3 Symptoms and signs
4 Treatment
- 4.1 Medication
- 4.2 Devices and surgery
5 External links
6 References
7 See also

Causes

Causes and contributing factors to congestive heart failure include: genetic family history of CHF, infection, alcohol ingestion, anemia, thyrotoxicosis, arrhythmia, and hypertension. The usual heart irritants can make CHF deadly: arterial plaque, stress, smoking, old age, no/little excercise, overworked heart, and obesity. In genetic family history of CHF, the cause is a weak heart having thinner muscle walls than usual, and often weakened further by one or more of the above heart irritants. Arterial plaque (caused by eating fatty or greasy foods) lines the inside of the arteries and heart, increasing blood pressure and tiring the heart. In obesity cases, the heart is squashed by fat surrounding it, giving it too little room to beat. The result is irregular heart beats causing inefficient blood pumping and a tired heart.

Classification

There are many different ways to categorize heart failure, including:

the side of the heart involved, (left heart failure versus right heart failure)
whether the abnormality is due to contraction or relaxation of the heart (systolicheart failure vs. diastolicheart failure)
whether the abnormality is due to low cardiac output or low systemic vascular resistance (low-output heart failure vs. high-output heart failure)

The NYHA functional classis a commonly used way to gauge the progression of CHF in a particular patient. This classification is used to determine how much CHF limits their lifestyle, and does not apply to a particular decompensated episode. Depending on symptoms, patients may move in either direction on the NYHA scale.

Class I: No symptoms at any level of exertion
Class II: Symptoms with heavy exertion
Class III: Symptoms with light exertion
Class IV: Symptoms with no exertion

Heart failure stages represent a newer classification that complements the NYHA classification.

Stage A: At risk for developing heart failure without evidence of cardiac dysfunction
Stage B: Evidence of cardiac dysfunction without symptoms
Stage C: Evidence of cardiac dysfunction with symptoms
Stage D: Symptoms of heart failure despite maximal therapy

An important feature of the staging classification is that patients can only progress in one direction: from Stage A to D. This is meant to reflect the progressive nature of heart failure.

Symptoms and signs

Signsof decompensated heart failure include pulmonary edema(fluid accumulation in the lungs), peripheral edema(fluid build-up in dependent portions of the body). Other physical examination findings include ralesheard on chest auscultation, an enlarged or pulsatileliver, and jugular venous distension. Reduced function in other organs can occur because they are not receiving enough blood. The patient may experience other organ conditions years before CHF is diagnosed.

Symptomsof decompensated heart failure include dyspnea(shortness of breath) on exertion, orthopnea(dyspnea that increases upon lying down), fatigue and paroxysmal nocturnal dyspnea("cardiac asthma", shortness of breath that occurs hours or minutes after lying down).

Treatment

Individuals with heart failure are sensitive to small shifts in their intravascularvolume status (the amount of fluid in their circulatory system). Increasing the volume in their circulatory system can cause symptoms and signs of decompensated heart failure, while decreasing the volume in the circulatory system can cause hypotension.

The treatment of CHF focuses on treating the symptoms and signs of CHF and preventing the progression of disease. If there is a reversible cause of the heart failure (e.g. infection, alcoholingestion, anemia, thyrotoxicosis, arrhythmia, or hypertension), that should be addressed as well. Reversible cause treatments can include excercise, eating healthy foods, reduction in salty foods, and reduction or abstinence of smoking and drinking alcohol.

Medication

Treating the signs and symptoms of CHF involves maintaining a euvolemicstate (normal fluid level in the circulatory system). This is done with the judicious use of diureticagents, vasodilatoragents, and positive inotropes.

Delaying the progression of heart failure involves the use of ACE inhibitors, beta blockers, and aldosterone inhibitors. These agents have been proven to improve survival in individuals with CHF. While the mechanism of improving is not entirely clear, it appears that these agents prevent remodelling of the heart and therefore prevent progression of dilatation of the left ventricle.

Devices and surgery

Patients with NYHA class III or IV, LVEF of 35% or less and a QRS interval of 120ms or more may benefit from bi-ventricular pacemaker(CRT) placement or surgical remodelling of the heart. These treatment modalities may make the patient symptomatically better, improving quality of life and in some trials have been proven to reduce mortality. In the recently completed COMPANION trial, cardiac resynchronization therapy(pacing the left ventricleas well as the right ventricle) has been shown to improve survival in individuals with NYHA class III or IV heart failure with a widened QRScomplex on EKG.² The CARE-HF trial, showed that patients receiving a Medtronic bi-ventricular pacemaker (CRT) and optimal medical therapy benefit from a 36% reduction in all cause mortality, and a reduction in cardiovascular related hospitalization.³

Additionally, patients with NYHA class II, III or IV, LVEF of 35% (without a QRS requirement) may benefit from an Implantable Converter Defibrillator(ICD), a device that is proven to reduce all cause mortality (death) by 23% compared to placebo. This mortality benefit was observed in patients who were already optimally managed on drug therapy.⁴

Another current treatment involves the use of left ventricular assist devices(LVADs). LVADs are battery-operated mechanical pump-type devices that are surgically implanted on the upper part of the abdomen. They take blood from the left ventricle and pump it through the aorta. LVADs are becoming more common and are often used by patients who have to wait for heart transplants. Acorn Cardiovascular, based in St. Paul, Minnesota, recently created the CorCap Cardiac Support Device (CSD), also known as the "heart sock." It is a dacron mesh that is placed around the heart. The elastic CSD works by mechanically restoring the contractility of the expanded heart. The CorCap CSD recently failed to be approved by the FDA.

The ultimate treatment is cardiac transplant surgery (heart transplant) or implantation of an artificial heart.

External links

Congestive Heart Failure informationfrom Seattle Children's Hospital Heart Center

References

1. ACC / AHA guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult(PDF Copy) 2. Bristow MR, Saxon LA, Boehmer J, et al for the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350:2140-2150. 3. Cleland JGF, Daubert J-C, Erdmann E, et al; the Cardiac Resynchronization -- Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005 March 7 N Engl J Med 2005; 10.1056/NEJMoa050496 4. Bardy GH, Lee KL, Mark DB, et al for the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352:225-237 5. Donatelle, Rebecca J. Health: The Basics. 6th ed. San Francisco: Pearson Education, Inc. 2005.